Insulin-like growth factor I and growth hormone (GH) treatment in GH-deficient humans: differential effects on protein, glucose, lipid, and calcium metabolism.

Mauras N, O'Brien KO, Welch S, Rini A, Helgeson K, Vieira NE, Yergey AL

The Journal of clinical endocrinology and metabolism1 Apr 2000Cited by 80 (Europe PMC)

PMID10770216DOI10.1210/jcem.85.4.6541PepBankPUB-10770216

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study25

25 results from studies that gave the peptide. 25 results from people.

01HumanRandomized controlled trialEfficacy outcome
In GH-deficient young adults, rhIGF-I increased fat-free mass.
In plain wordsIn GH-deficient young adults, rhIGF-I increased fat-free mass from baseline.
Peptide
IGF-1 (mecasermin)
Outcome
IncreaseFat-free mass
Study
n = 8
Outcome group
Body composition · Metabolic and weight
Studied dose
60 microg/kg twice daily · subcutaneous · 8 weeksAs given in this study (human).
Source sentences
Summary
In the doses administered, rhIGF-I and rhGH both increased fat-free mass and decreased the percent fat mass, with a more robust decrease in the percent fat mass after rhGH; both were associated with an increase in whole body protein synthesis rates and a decrease in protein oxidation.
1 context sentence(design, population, supporting numbers)
Summary · context
We examined the effects of recombinant human (rh) insulin-like growth factor I (IGF-I) vs. rhGH in a variety of metabolic paths in a group of eight severely GH-deficient young adults using an array of contemporary tools.
Report a problemFND-1077021601
02HumanRandomized controlled trialEfficacy outcome
In GH-deficient young adults, rhIGF-I decreased percent fat mass.
In plain wordsIn GH-deficient young adults, rhIGF-I decreased body fat percentage from baseline.
Peptide
IGF-1 (mecasermin)
Outcome
DecreasePercent fat mass
Study
n = 8
Outcome group
Body composition · Metabolic and weight
Studied dose
60 microg/kg twice daily · subcutaneous · 8 weeksAs given in this study (human).
Source sentences
Summary
In the doses administered, rhIGF-I and rhGH both increased fat-free mass and decreased the percent fat mass, with a more robust decrease in the percent fat mass after rhGH; both were associated with an increase in whole body protein synthesis rates and a decrease in protein oxidation.
1 context sentence(design, population, supporting numbers)
Summary · context
We examined the effects of recombinant human (rh) insulin-like growth factor I (IGF-I) vs. rhGH in a variety of metabolic paths in a group of eight severely GH-deficient young adults using an array of contemporary tools.
Report a problemFND-1077021602
03HumanRandomized controlled trialEfficacy outcome
In GH-deficient young adults, rhIGF-I reduced percent fat mass less robustly than rhGH.
In plain wordsIn GH-deficient young adults, rhIGF-I reduced body fat percentage less than rhGH.
Peptide
IGF-1 (mecasermin)
Outcome
IncreasePercent fat mass compared with rhGH
Study
n = 8
Comparator
rhGH
Outcome group
Body composition · Metabolic and weight
Studied dose
60 microg/kg twice daily · subcutaneous · 8 weeksAs given in this study (human).
Source sentences
Summary
In the doses administered, rhIGF-I and rhGH both increased fat-free mass and decreased the percent fat mass, with a more robust decrease in the percent fat mass after rhGH; both were associated with an increase in whole body protein synthesis rates and a decrease in protein oxidation.
1 context sentence(design, population, supporting numbers)
Summary · context
We examined the effects of recombinant human (rh) insulin-like growth factor I (IGF-I) vs. rhGH in a variety of metabolic paths in a group of eight severely GH-deficient young adults using an array of contemporary tools.
Report a problemFND-1077021603
04HumanRandomized controlled trialEfficacy outcome
In GH-deficient young adults, rhIGF-I increased whole body protein synthesis rates.
In plain wordsIn GH-deficient young adults, rhIGF-I increased protein synthesis from baseline.
Peptide
IGF-1 (mecasermin)
Outcome
IncreaseWhole body protein synthesis
Study
n = 8
Outcome group
Protein and amino acid metabolism · Metabolic and weight
Studied dose
60 microg/kg twice daily · subcutaneous · 8 weeksAs given in this study (human).
Source sentences
Summary
In the doses administered, rhIGF-I and rhGH both increased fat-free mass and decreased the percent fat mass, with a more robust decrease in the percent fat mass after rhGH; both were associated with an increase in whole body protein synthesis rates and a decrease in protein oxidation.
1 context sentence(design, population, supporting numbers)
Summary · context
We examined the effects of recombinant human (rh) insulin-like growth factor I (IGF-I) vs. rhGH in a variety of metabolic paths in a group of eight severely GH-deficient young adults using an array of contemporary tools.
Report a problemFND-1077021604
05HumanRandomized controlled trialEfficacy outcome
In GH-deficient young adults, rhIGF-I decreased protein oxidation.
In plain wordsIn GH-deficient young adults, rhIGF-I decreased protein oxidation from baseline.
Peptide
IGF-1 (mecasermin)
Outcome
DecreaseProtein oxidation
Study
n = 8
Outcome group
Protein and amino acid metabolism · Metabolic and weight
Studied dose
60 microg/kg twice daily · subcutaneous · 8 weeksAs given in this study (human).
Source sentences
Summary
In the doses administered, rhIGF-I and rhGH both increased fat-free mass and decreased the percent fat mass, with a more robust decrease in the percent fat mass after rhGH; both were associated with an increase in whole body protein synthesis rates and a decrease in protein oxidation.
1 context sentence(design, population, supporting numbers)
Summary · context
We examined the effects of recombinant human (rh) insulin-like growth factor I (IGF-I) vs. rhGH in a variety of metabolic paths in a group of eight severely GH-deficient young adults using an array of contemporary tools.
Report a problemFND-1077021605
06HumanRandomized controlled trialEfficacy outcome
In GH-deficient young adults, rhIGF-I did not affect isokinetic skeletal muscle strength.
In plain wordsIn GH-deficient young adults, rhIGF-I did not change isokinetic muscle strength from baseline.
Peptide
IGF-1 (mecasermin)
Outcome
No significant changeIsokinetic muscle strength
Study
n = 8
Outcome group
Exercise and physical function · Musculoskeletal
Studied dose
60 microg/kg twice daily · subcutaneous · 8 weeksAs given in this study (human).
Source sentences
Summary
Neither hormone affected isokinetic or isometric measures of skeletal muscle strength.
1 context sentence(design, population, supporting numbers)
Summary · context
We examined the effects of recombinant human (rh) insulin-like growth factor I (IGF-I) vs. rhGH in a variety of metabolic paths in a group of eight severely GH-deficient young adults using an array of contemporary tools.
Report a problemFND-1077021606
07HumanRandomized controlled trialEfficacy outcome
In GH-deficient young adults, rhIGF-I did not affect isometric skeletal muscle strength.
In plain wordsIn GH-deficient young adults, rhIGF-I did not change isometric muscle strength from baseline.
Peptide
IGF-1 (mecasermin)
Outcome
No significant changeIsometric muscle strength
Study
n = 8
Outcome group
Exercise and physical function · Musculoskeletal
Studied dose
60 microg/kg twice daily · subcutaneous · 8 weeksAs given in this study (human).
Source sentences
Summary
Neither hormone affected isokinetic or isometric measures of skeletal muscle strength.
1 context sentence(design, population, supporting numbers)
Summary · context
We examined the effects of recombinant human (rh) insulin-like growth factor I (IGF-I) vs. rhGH in a variety of metabolic paths in a group of eight severely GH-deficient young adults using an array of contemporary tools.
Report a problemFND-1077021607
08HumanRandomized controlled trialEfficacy outcome
In GH-deficient young adults, rhIGF-I was less potent than rhGH at increasing lipid oxidation rates.
In plain wordsIn GH-deficient young adults, rhIGF-I increased lipid oxidation less than rhGH.
Peptide
IGF-1 (mecasermin)
Outcome
DecreaseLipid oxidation
Study
n = 8
Comparator
rhGH
Outcome group
Lipids · Metabolic and weight
Studied dose
60 microg/kg twice daily · subcutaneous · 8 weeksAs given in this study (human).
Source sentences
Summary
However, rhGH was more potent than rhIGF-I at increasing lipid oxidation rates and improving plasma lipid profiles.
1 context sentence(design, population, supporting numbers)
Summary · context
We examined the effects of recombinant human (rh) insulin-like growth factor I (IGF-I) vs. rhGH in a variety of metabolic paths in a group of eight severely GH-deficient young adults using an array of contemporary tools.
Report a problemFND-1077021608
09HumanRandomized controlled trialEfficacy outcome
In GH-deficient young adults, rhGH was more potent than rhIGF-I at improving plasma lipid profiles.
In plain wordsIn GH-deficient young adults, growth hormone improved blood lipid profiles more than rhIGF-I did.
Peptide
IGF-1 (mecasermin)
Outcome
DecreasePlasma lipid profile improvement compared with rhGH
Study
n = 8
Comparator
rhGH
Outcome group
Lipids · Metabolic and weight
Studied dose
60 microg/kg twice daily · subcutaneous · 8 weeksAs given in this study (human).
Source sentences
Summary
However, rhGH was more potent than rhIGF-I at increasing lipid oxidation rates and improving plasma lipid profiles.
1 context sentence(design, population, supporting numbers)
Summary · context
We examined the effects of recombinant human (rh) insulin-like growth factor I (IGF-I) vs. rhGH in a variety of metabolic paths in a group of eight severely GH-deficient young adults using an array of contemporary tools.
Report a problemFND-1077021609
10HumanRandomized controlled trialEfficacy outcome
In GH-deficient young adults, rhIGF-I increased hepatic glucose output.
In plain wordsIn GH-deficient young adults, rhIGF-I increased glucose production by the liver from baseline.
Peptide
IGF-1 (mecasermin)
Outcome
IncreaseHepatic glucose output
Study
n = 8
Outcome group
Glycemic control · Metabolic and weight
Studied dose
60 microg/kg twice daily · subcutaneous · 8 weeksAs given in this study (human).
Source sentences
Summary
Both hormones increased hepatic glucose output, but rhGH treatment was also associated with decreased carbohydrate oxidation and increased glucose and insulin concentrations, indicating subtle insulin resistance.
1 context sentence(design, population, supporting numbers)
Summary · context
We examined the effects of recombinant human (rh) insulin-like growth factor I (IGF-I) vs. rhGH in a variety of metabolic paths in a group of eight severely GH-deficient young adults using an array of contemporary tools.
Report a problemFND-1077021610
11HumanRandomized controlled trialEfficacy outcome
In GH-deficient young adults, rhIGF-I did not significantly affect bone calcium fluxes.
In plain wordsIn GH-deficient young adults, rhIGF-I did not significantly change bone calcium movement from baseline.
Peptide
IGF-1 (mecasermin)
Outcome
No significant changeBone calcium fluxes
Study
n = 8
Outcome group
Bone and joint · Musculoskeletal
Studied dose
60 microg/kg twice daily · subcutaneous · 8 weeksAs given in this study (human).
Source sentences
Summary
Neither hormone significantly affected bone calcium fluxes, supporting the concept that these hormones, by themselves, are not pivotal in bone calcium metabolism.
1 context sentence(design, population, supporting numbers)
Summary · context
We examined the effects of recombinant human (rh) insulin-like growth factor I (IGF-I) vs. rhGH in a variety of metabolic paths in a group of eight severely GH-deficient young adults using an array of contemporary tools.
Report a problemFND-1077021611
12HumanRandomized controlled trialEfficacy outcome
In severely GH-deficient young adults, rhGH decreased percent fat mass more than rhIGF-I.
In plain wordsIn young adults with severe GH deficiency, rhGH decreased body fat percentage more than rhIGF-I.
Peptide
HGH (somatotropin)
Outcome
DecreasePercent fat mass versus rhIGF-I
Study
n = 8
Comparator
rhIGF-I
Outcome group
Body composition · Metabolic and weight
Studied dose
12.5 microg/kg-day · subcutaneous · 8 weeksAs given in this study (human).
Source sentences
Summary
In the doses administered, rhIGF-I and rhGH both increased fat-free mass and decreased the percent fat mass, with a more robust decrease in the percent fat mass after rhGH;
2 context sentences(design, population, supporting numbers)
Summary · context
We examined the effects of recombinant human (rh) insulin-like growth factor I (IGF-I) vs. rhGH in a variety of metabolic paths in a group of eight severely GH-deficient young adults using an array of contemporary tools.
Summary · context
then 8 weeks ofrhGH (12.5 microg/kg-day, sc); the treatment order was randomized.
Report a problemFND-1077021614
13HumanRandomized controlled trialEfficacy outcome
In severely GH-deficient young adults, rhGH increased lipid oxidation more than rhIGF-I.
In plain wordsIn young adults with severe GH deficiency, rhGH increased fat burning more than rhIGF-I.
Peptide
HGH (somatotropin)
Outcome
IncreaseLipid oxidation
Study
n = 8
Comparator
rhIGF-I
Outcome group
Lipids · Metabolic and weight
Studied dose
12.5 microg/kg-day · subcutaneous · 8 weeksAs given in this study (human).
Source sentences
Summary
However, rhGH was more potent than rhIGF-I at increasing lipid oxidation rates and improving plasma lipid profiles.
2 context sentences(design, population, supporting numbers)
Summary · context
We examined the effects of recombinant human (rh) insulin-like growth factor I (IGF-I) vs. rhGH in a variety of metabolic paths in a group of eight severely GH-deficient young adults using an array of contemporary tools.
Summary · context
then 8 weeks ofrhGH (12.5 microg/kg-day, sc); the treatment order was randomized.
Report a problemFND-1077021619
14HumanRandomized controlled trialEfficacy outcome
In severely GH-deficient young adults, rhGH improved plasma lipid profiles more than rhIGF-I, without individual lipid results.
In plain wordsIn young adults with severe GH deficiency, rhGH improved blood fat profiles more than rhIGF-I.
Peptide
HGH (somatotropin)
Outcome
Direction not reportedPlasma lipid profiles
Study
n = 8
Comparator
rhIGF-I
Outcome group
Lipids · Metabolic and weight
Studied dose
12.5 microg/kg-day · subcutaneous · 8 weeksAs given in this study (human).
Source sentences
Summary
However, rhGH was more potent than rhIGF-I at increasing lipid oxidation rates and improving plasma lipid profiles.
2 context sentences(design, population, supporting numbers)
Summary · context
We examined the effects of recombinant human (rh) insulin-like growth factor I (IGF-I) vs. rhGH in a variety of metabolic paths in a group of eight severely GH-deficient young adults using an array of contemporary tools.
Summary · context
then 8 weeks ofrhGH (12.5 microg/kg-day, sc); the treatment order was randomized.
Report a problemFND-1077021620
15HumanNon-randomized trialEfficacy outcome
In severely GH-deficient young adults, rhGH increased fat-free mass versus before treatment.
In plain wordsIn young adults with severe GH deficiency, rhGH increased fat-free mass versus before treatment.
Peptide
HGH (somatotropin)
Outcome
IncreaseFat-free mass
Study
n = 8
Comparator
Before rhGH treatment
Outcome group
Body composition · Musculoskeletal
Studied dose
12.5 microg/kg-day · subcutaneous · 8 weeksAs given in this study (human).
Source sentences
Summary
In the doses administered, rhIGF-I and rhGH both increased fat-free mass and decreased the percent fat mass, with a more robust decrease in the percent fat mass after rhGH;
2 context sentences(design, population, supporting numbers)
Summary · context
We examined the effects of recombinant human (rh) insulin-like growth factor I (IGF-I) vs. rhGH in a variety of metabolic paths in a group of eight severely GH-deficient young adults using an array of contemporary tools.
Summary · context
then 8 weeks ofrhGH (12.5 microg/kg-day, sc); the treatment order was randomized.
Report a problemFND-1077021612
16HumanNon-randomized trialEfficacy outcome
In severely GH-deficient young adults, rhGH decreased percent fat mass versus before treatment.
In plain wordsIn young adults with severe GH deficiency, rhGH decreased percent fat mass versus before treatment.
Peptide
HGH (somatotropin)
Outcome
DecreasePercent fat mass
Study
n = 8
Comparator
Before rhGH treatment
Outcome group
Body composition · Metabolic and weight
Studied dose
12.5 microg/kg-day · subcutaneous · 8 weeksAs given in this study (human).
Source sentences
Summary
In the doses administered, rhIGF-I and rhGH both increased fat-free mass and decreased the percent fat mass, with a more robust decrease in the percent fat mass after rhGH;
2 context sentences(design, population, supporting numbers)
Summary · context
We examined the effects of recombinant human (rh) insulin-like growth factor I (IGF-I) vs. rhGH in a variety of metabolic paths in a group of eight severely GH-deficient young adults using an array of contemporary tools.
Summary · context
then 8 weeks ofrhGH (12.5 microg/kg-day, sc); the treatment order was randomized.
Report a problemFND-1077021613
17HumanNon-randomized trialEfficacy outcome
In severely GH-deficient young adults, rhGH increased whole body protein synthesis versus before treatment.
In plain wordsIn young adults with severe GH deficiency, rhGH increased whole body protein production versus before treatment.
Peptide
HGH (somatotropin)
Outcome
IncreaseWhole body protein synthesis
Study
n = 8
Comparator
Before rhGH treatment
Outcome group
Protein and amino acid metabolism · Musculoskeletal
Studied dose
12.5 microg/kg-day · subcutaneous · 8 weeksAs given in this study (human).
Source sentences
Summary
both were associated with an increase in whole body protein synthesis rates and a decrease in protein oxidation.
2 context sentences(design, population, supporting numbers)
Summary · context
We examined the effects of recombinant human (rh) insulin-like growth factor I (IGF-I) vs. rhGH in a variety of metabolic paths in a group of eight severely GH-deficient young adults using an array of contemporary tools.
Summary · context
then 8 weeks ofrhGH (12.5 microg/kg-day, sc); the treatment order was randomized.
Report a problemFND-1077021615
18HumanNon-randomized trialEfficacy outcome
In severely GH-deficient young adults, rhGH decreased protein oxidation versus before treatment.
In plain wordsIn young adults with severe GH deficiency, rhGH decreased protein burning versus before treatment.
Peptide
HGH (somatotropin)
Outcome
DecreaseProtein oxidation
Study
n = 8
Comparator
Before rhGH treatment
Outcome group
Protein and amino acid metabolism · Metabolic and weight
Studied dose
12.5 microg/kg-day · subcutaneous · 8 weeksAs given in this study (human).
Source sentences
Summary
both were associated with an increase in whole body protein synthesis rates and a decrease in protein oxidation.
2 context sentences(design, population, supporting numbers)
Summary · context
We examined the effects of recombinant human (rh) insulin-like growth factor I (IGF-I) vs. rhGH in a variety of metabolic paths in a group of eight severely GH-deficient young adults using an array of contemporary tools.
Summary · context
then 8 weeks ofrhGH (12.5 microg/kg-day, sc); the treatment order was randomized.
Report a problemFND-1077021616
19HumanNon-randomized trialEfficacy outcome
In severely GH-deficient young adults, rhGH did not affect isokinetic skeletal muscle strength versus before treatment.
In plain wordsIn young adults with severe GH deficiency, rhGH did not change isokinetic muscle strength versus before treatment.
Peptide
HGH (somatotropin)
Outcome
No significant changeIsokinetic muscle strength
Study
n = 8
Comparator
Before rhGH treatment
Outcome group
Exercise and physical function · Musculoskeletal
Studied dose
12.5 microg/kg-day · subcutaneous · 8 weeksAs given in this study (human).
Source sentences
Summary
Neither hormone affected isokinetic or isometric measures of skeletal muscle strength.
2 context sentences(design, population, supporting numbers)
Summary · context
We examined the effects of recombinant human (rh) insulin-like growth factor I (IGF-I) vs. rhGH in a variety of metabolic paths in a group of eight severely GH-deficient young adults using an array of contemporary tools.
Summary · context
then 8 weeks ofrhGH (12.5 microg/kg-day, sc); the treatment order was randomized.
Report a problemFND-1077021617
20HumanNon-randomized trialEfficacy outcome
In severely GH-deficient young adults, rhGH did not affect isometric skeletal muscle strength versus before treatment.
In plain wordsIn young adults with severe GH deficiency, rhGH did not change isometric muscle strength versus before treatment.
Peptide
HGH (somatotropin)
Outcome
No significant changeIsometric muscle strength
Study
n = 8
Comparator
Before rhGH treatment
Outcome group
Exercise and physical function · Musculoskeletal
Studied dose
12.5 microg/kg-day · subcutaneous · 8 weeksAs given in this study (human).
Source sentences
Summary
Neither hormone affected isokinetic or isometric measures of skeletal muscle strength.
2 context sentences(design, population, supporting numbers)
Summary · context
We examined the effects of recombinant human (rh) insulin-like growth factor I (IGF-I) vs. rhGH in a variety of metabolic paths in a group of eight severely GH-deficient young adults using an array of contemporary tools.
Summary · context
then 8 weeks ofrhGH (12.5 microg/kg-day, sc); the treatment order was randomized.
Report a problemFND-1077021618
21HumanNon-randomized trialEfficacy outcome
In severely GH-deficient young adults, rhGH increased hepatic glucose output versus before treatment.
In plain wordsIn young adults with severe GH deficiency, rhGH increased liver glucose production versus before treatment.
Peptide
HGH (somatotropin)
Outcome
IncreaseHepatic glucose output
Study
n = 8
Comparator
Before rhGH treatment
Outcome group
Glycemic control · Metabolic and weight
Studied dose
12.5 microg/kg-day · subcutaneous · 8 weeksAs given in this study (human).
Source sentences
Summary
Both hormones increased hepatic glucose output, but rhGH treatment was also associated with decreased carbohydrate oxidation and increased glucose and insulin concentrations, indicating subtle insulin resistance.
2 context sentences(design, population, supporting numbers)
Summary · context
We examined the effects of recombinant human (rh) insulin-like growth factor I (IGF-I) vs. rhGH in a variety of metabolic paths in a group of eight severely GH-deficient young adults using an array of contemporary tools.
Summary · context
then 8 weeks ofrhGH (12.5 microg/kg-day, sc); the treatment order was randomized.
Report a problemFND-1077021621
22HumanNon-randomized trialEfficacy outcome
In severely GH-deficient young adults, rhGH decreased carbohydrate oxidation versus before treatment.
In plain wordsIn young adults with severe GH deficiency, rhGH decreased carbohydrate burning versus before treatment.
Peptide
HGH (somatotropin)
Outcome
DecreaseCarbohydrate oxidation
Study
n = 8
Comparator
Before rhGH treatment
Outcome group
Glycemic control · Metabolic and weight
Studied dose
12.5 microg/kg-day · subcutaneous · 8 weeksAs given in this study (human).
Source sentences
Summary
Both hormones increased hepatic glucose output, but rhGH treatment was also associated with decreased carbohydrate oxidation and increased glucose and insulin concentrations, indicating subtle insulin resistance.
2 context sentences(design, population, supporting numbers)
Summary · context
We examined the effects of recombinant human (rh) insulin-like growth factor I (IGF-I) vs. rhGH in a variety of metabolic paths in a group of eight severely GH-deficient young adults using an array of contemporary tools.
Summary · context
then 8 weeks ofrhGH (12.5 microg/kg-day, sc); the treatment order was randomized.
Report a problemFND-1077021622
23HumanNon-randomized trialEfficacy outcome
In severely GH-deficient young adults, rhGH increased plasma glucose concentrations versus before treatment.
In plain wordsIn young adults with severe GH deficiency, rhGH increased blood glucose versus before treatment.
Peptide
HGH (somatotropin)
Outcome
IncreaseGlucose concentration
Study
n = 8
Comparator
Before rhGH treatment
Outcome group
Glycemic control · Metabolic and weight
Studied dose
12.5 microg/kg-day · subcutaneous · 8 weeksAs given in this study (human).
Source sentences
Summary
Both hormones increased hepatic glucose output, but rhGH treatment was also associated with decreased carbohydrate oxidation and increased glucose and insulin concentrations, indicating subtle insulin resistance.
2 context sentences(design, population, supporting numbers)
Summary · context
We examined the effects of recombinant human (rh) insulin-like growth factor I (IGF-I) vs. rhGH in a variety of metabolic paths in a group of eight severely GH-deficient young adults using an array of contemporary tools.
Summary · context
then 8 weeks ofrhGH (12.5 microg/kg-day, sc); the treatment order was randomized.
Report a problemFND-1077021623
24HumanNon-randomized trialEfficacy outcome
In severely GH-deficient young adults, rhGH increased plasma insulin concentrations versus before treatment.
In plain wordsIn young adults with severe GH deficiency, rhGH increased blood insulin versus before treatment.
Peptide
HGH (somatotropin)
Outcome
IncreaseInsulin concentration
Study
n = 8
Comparator
Before rhGH treatment
Outcome group
Glycemic control · Metabolic and weight
Studied dose
12.5 microg/kg-day · subcutaneous · 8 weeksAs given in this study (human).
Source sentences
Summary
Both hormones increased hepatic glucose output, but rhGH treatment was also associated with decreased carbohydrate oxidation and increased glucose and insulin concentrations, indicating subtle insulin resistance.
2 context sentences(design, population, supporting numbers)
Summary · context
We examined the effects of recombinant human (rh) insulin-like growth factor I (IGF-I) vs. rhGH in a variety of metabolic paths in a group of eight severely GH-deficient young adults using an array of contemporary tools.
Summary · context
then 8 weeks ofrhGH (12.5 microg/kg-day, sc); the treatment order was randomized.
Report a problemFND-1077021624
25HumanNon-randomized trialEfficacy outcome
In severely GH-deficient young adults, rhGH did not significantly affect bone calcium fluxes versus before treatment.
In plain wordsIn young adults with severe GH deficiency, rhGH did not significantly change bone calcium movement versus before treatment.
Peptide
HGH (somatotropin)
Outcome
No significant changeBone calcium fluxes
Study
n = 8
Comparator
Before rhGH treatment
Outcome group
Bone and joint · Musculoskeletal
Studied dose
12.5 microg/kg-day · subcutaneous · 8 weeksAs given in this study (human).
Source sentences
Summary
Neither hormone significantly affected bone calcium fluxes, supporting the concept that these hormones, by themselves, are not pivotal in bone calcium metabolism.
2 context sentences(design, population, supporting numbers)
Summary · context
We examined the effects of recombinant human (rh) insulin-like growth factor I (IGF-I) vs. rhGH in a variety of metabolic paths in a group of eight severely GH-deficient young adults using an array of contemporary tools.
Summary · context
then 8 weeks ofrhGH (12.5 microg/kg-day, sc); the treatment order was randomized.
Report a problemFND-1077021625

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
27 Oct 2026, 16:36 UTC
Study data updated · source update from Europe PMC
Version 2
14 Oct 2026, 05:02 UTC
Study results updated
Version 1
14 Oct 2026, 01:46 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.